Skip to content

Evidence

Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-World Evidence in >500,000 Patients

RSNA: Podium Presentation
McCabe et al. 2025

 

Interpretive performance in screening mammograms (SMGs) varies widely. An AI-driven workflow was deployed at scale, and performance before and after implementation was compared between radiologists with and without fellowship training in breast or women’s imaging. The Multistage AI-Driven workflow significantly improved CDR and PPV1 for General radiologists to levels comparable with Fellowship-trained radiologists.

Large-Scale Deployment of a Multistage AI-Driven Workflow Increases Detection of Deadlier Breast Cancers

RSNA: Poster Presentation
Louis et al. 2025

 

This study assesses the cancer subtypes detected in a large-scale deployment of a multistage AI-driven workflow compared to the standard of care (SOC). Employing the multistage AI-driven workflow significantly improved clinical outcomes in terms of CDR in a cohort of over 2400 cancers, with the majority of cancers detected being clinically relevant and no corresponding increase in the proportion of DCIS, showing benefits for screening mammography.

Equitable Impact of an AI-driven Breast Cancer Screening Workflow in Real-World US-Wide Deployment

Nature Health
Louis et al. Nov 2025

 

Artificial intelligence shows promising results for improving early breast cancer detection and overall screening outcomes. Here the AI-Supported Safeguard Review Evaluation (ASSURE) study evaluates an AI workflow on digital breast tomosynthesis exams from women across four states to optimize early cancer detection. Implementation of the AI workflow improved screening effectiveness with equitable benefits.

AI Driven Safeguard Review Process Helps Detect Aggressive Breast Cancers

RSNA: Poster Presentation
Kim et al. 2024

 

An AI-driven safeguard review process was implemented prospectively, and its custom-built AI algorithm was used to flag the most suspicious screening DBT exams that had not been recalled by the initial interpreting radiologist. An expert breast imaging specialist performed a second, safeguard review of the 2,296 flagged exams. This resulted in the detection of 41 additional cancers, mostly invasive, 22.0% of which were deemed aggressive.

Impact of a Categorical AI System for Digital Breast Tomosynthesis on Breast Cancer Interpretation by Both General Radiologists and Breast Imaging Specialists

Radiology Artificial Intelligence
Kim et al. Feb 2024

 

The performance of 18 general radiologists and breast imaging specialists (9 generalists, 9 specialists) was evaluated with and without the aid of a custom-built categorical AI system. The categorical AI system helped improve overall radiologist interpretation performance of DBT screening mammograms for both general radiologists and breast imaging specialists and across various patient subgroups and breast cancer characteristics.

Robust Breast Cancer Detection in Mammography and Digital Breast Tomosynthesis Using an Annotation-Efficient Deep Learning Approach

Nature Medicine
Lotter et al. Jan 2021

 

DeepHealth’s deep-learning algorithm achieves state of the art performance in mammogram classification. The AI model was compared to 5 readers in a reader study of 131 index cancers and 154 confirmed negatives. The model showed robust and generalizable performance, reporting an Area Under the Curve (AUC) of 0.945 and outperforming all radiologists with a sensitivity 14% higher than the average radiologist sensitivity.

Disclaimers: DeepHealth Prostate is manufactured as Quantib Prostate by Quantib BV for DeepHealth Inc., DeepHealth Lung is manufactured as Veye Lung Nodules by Aidence BV for DeepHealth Inc., DeepHeath Lung Tracker is manufactured as Veye Clinic by Aidence BV for DeepHealth Inc. and DeepHealth Brain is manufactured as Quantib ND by Quantib BV for DeepHealth Inc. Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact us